Evaluation of the use of a standard input function for compartment analysis of [123I]iomazenil data: Factors influencing the quantitative results

Annals of Nuclear Medicine

Volumn 18, Issue 7, 2004, Pages 563-572

  Seike, Yujiro ^a   Hashikawa, Kazuo ^b   Oku, Naohiko ^c   Moriwaki, Hiroshi ^d   Yamamoto, Haruko ^d   Fukuchi, Kazuki ^d   Watanabe, Yoshiyuki ^e   Matsumoto, Masayasu ^f   Hori, Masatsugu ^e   Nishimura, Tsunehiko ^g  

^a National Hospital Organization   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Kinetic analysis; SPECT

Indexed keywords

BENZODIAZEPINE RECEPTOR BLOCKING AGENT; IODINE 123; IOMAZENIL;

ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CALCULATION; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RECEPTOR BINDING; SAMPLING; SIMULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARD; STANDARD INPUT FUNCTION;

EID: 10044270693     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984577     Document Type: Article

References (37)

1. Holl K, Deisenhammer E, Dauth J, Carmann H, Schubiger PA. Imaging benzodiazepine receptors in the human brain by single photon emission computed tomography (SPECT). Int J Rad Appl Instrum B 1989; 16: 759-763.
2. Beer HF, Blauenstein PA, Hasler PH, Delaloye B, Riccabona G, Bangerl I, et al. In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 1990; 31: 1007-1014.
3. 125I-Ro16-0154: potential probe for SPECT brain imaging. Life Sci 1990; 47: 1535-1546.
4. Innis RB, al Tikriti MS, Zoghbi SS, Baldwin RM, Sybirska EH, Laruelle MA, et al. SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curves [see comments]. J Nucl Med 1991; 32: 1754-1761.
5. 123I]Ro 16-0154. Eur J Pharmacol 1991; 193: 249-252.
6. 123I]iomazenil in healthy human subjects. Psychiatry Res 1992; 45: 67-77.
7. Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 1988; 2: 863-866.
8. Johnson EW, de Lanerolle NC, Kim JH, Sundaresan S, Spencer DD, Mattson RH, et al. "Central" and "peripheral" benzodiazepine receptors: opposite changes in human epileptogenic tissue. Neurology 1992; 42: 811-815.
9. Kiuchi Y, Kobayashi T, Takeuchi J, Shimizu H, Ogata H, Toru M. Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. Eur Arch Psychiatry Neurol Sci 1989; 239: 71-78.
10. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 1992; 12: 924-929.
11. Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci 1994; 244: 49-51.
12. 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Biol Psychiatry 1998; 43: 660-665.
13. Onodera H, Sato G, Kogure K. GABA and benzodiazepine receptors in the gerbil brain after transient ischemia: demonstration by quantitative receptor autoradiography. J Cereb Blood Flow Metab 1987; 7: 82-88.
14. Penney JB Jr, Young AB. Quantitative autoradiography of neurotransmitter receptors in Huntington disease. Neurology 1982; 32: 1391-1395.
15. Walker FO, Young AB, Penney JB, Dovorini Zis K, Shoulson I. Benzodiazepine and GABA receptors in early Huntington's disease. Neurology 1984; 34: 1237-1240.
16. Whitehouse PJ, Trifiletti RR, Jones BE, Folstein S, Price DL, Snyder SH, et al. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Ann Neurol 1985; 18: 202-210.
17. Mintun MA, Raichle ME, Kilbourn MR, Woolen GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-227.
18. Perlmutter JS, Larson KB, Raichle ME, Markham J, Mintun MA, Kilbourn MR, et al. Strategies for in vivo measurement of receptor binding using positron emission tomography. J Cereb Blood Flow Metab 1986; 6: 154-169.
19. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991; 11: 735-744.
20. 11C]flumazenil. J Cereb Blood Flow Metab 1991 ; 11: 745-752.
21. Abi Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, et al. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med 1994; 35: 228-238.
22. Abi Dargham A, Gandelman M, Zoghbi SS, Laruelle M, Baldwin RM, Randall P, et al. Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. J Nucl Med 1995; 36: 167-175.
23. Onishi Y, Yonekura Y, Mukai T, Nishizawa S, Tanaka F, Okazawa H, et al. Simple quantification of benzodiazepine receptor binding and ligand transport using iodine-123-iomazenil and two SPECT scans. J Nucl Med 1995; 36: 1201-1210.
24. Buck A, Westera G, vonSchulthess GK, Burger C. Modeling alternatives for cerebral carbon-11-iomazenil kinetics. J Nucl Med 1996; 37: 699-705.
25. Yonekura Y, Nishizawa S, Tanaka F, Ishizu K, Okazawa H, Fujita T, et al. Phase 1 clinical study of I23l-iomazenil: a new probe to evaluate central-type benzodiazepine receptor with SPECT. KAKU ICAKU (Jpn J Nucl Med) 1995; 32:87-97
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
27. 123I]iomazenil in human and non-human primates. Int J Rad Appl Instrum B 1992; 19: 881-888.
28. Phelps ME, Huang SC, Huffman EJ, Kuhl DE. Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. J Nucl Med 1979; 20: 328-334.
29. Gill PE, Murray W, Sanders MA, Wright MH. Procedures for Optimization Problems with a Mixture of Bounds and General Linear Constraints. ACM Trans Math Software 1984; 10: 282-298.
30. Schittowski K. NLQPL: A FORTRAN-subroutine Solving Constrained Nonlinear Programming Problems. Operations Research 1985; 5: 485-500.
31. Dey HM, Seibyl JP, Stubbs JB, Zoghbi SS, Baldwin RM, Smith EO, et al. Human biodistribution anddosimetry of the SPECT benzodiazepine receptor radioligand iodine-123-iomazenil. J Nucl Med 1994; 35: 399-404.
32. Bruno B, Ilaria B, Pliergiuseppe O, Tolmino C. How gender and age affect Iodine-131-OH andTechnetium-99m-MAG3 clearance. J Nucl Med Technol 2000; 28: 156-158.
33. 123I]iomazenil binding to benzodiazepine receptors in non-human primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 1994; 14:453-465.
34. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
35. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-158.
36. Ito H, Goto R, Koyama M, Kawashima R, Ono S, Sato K, et al. A simple method for the quantification of benzodiazepine receptors using iodine-123 iomazenil and single-photon emission tomography. Eur J Nucl Med 1996; 23: 782-791.
37. Ito H, Koyama M, Goto R, Kawashima R, Ono S, Atsumi H, et al. Cerebral blood flow measurement with iodine-123-IMP SPECT, calibrated standard input function and venous blood sampling [see comments]. J Nucl Med 1995; 36: 2339-2342.